Ponstan

Mefenamic acid

Symptomatic relief of RA eg, Still's disease, OA & pain eg, muscular, traumatic & dental pain, headaches, post-op & postpartum pain; primary dysmenorrhea. Menorrhagia due to dysfunctional causes or presence of IUD when organic pelvic pathology has been excluded. Premenstrual syndrome. Relief of pyrexia in ped patients >6 mth.

Mild to moderate pain, RA, OA Adult & adolescent >14 yr 500 mg tds. Dysmenorrhea, menorrhagia, premenstrual syndrome 500 mg tds. Still's disease or antipyretic Infant & childn >6 mth-14 yr 19.5-25 mg/kg in divided doses tds.

Should be taken with food: Take immediately after meals.

Hypersensitivity. Cross-sensitivity to aspirin or other NSAIDs. Active ulceration or chronic inflammation of upper or lower GI tract. Preexisting renal disease. Peri-op pain in the setting of CABG surgery. Severe renal, hepatic & heart failure.

Discontinue use at 1st appearance of skin rash, mucosal lesions or any other signs of hypersensitivity & if abnormal liver tests persist or worsen, if clinical signs & symptoms consistent w/ liver disease develops or systemic manifestations occur. Increased risk of serious CV thrombotic events, MI & stroke. Patients w/ prior history of or active GI disease eg, ulceration, bleeding or inflammation or other risk factors associated w/ PUD eg, alcoholism, smoking & corticosteroid therapy; HTN, compromised cardiac function & other conditions predisposing to, or worsened by fluid retention; preexisting CHF; liver cirrhosis, nephrotic syndrome, overt renal disease. Serious skin reactions eg, exfoliative dermatitis, Stevens-Johnson syndrome & toxic epidermal necrolysis. Avoid concomitant use w/ non-aspirin NSAIDs including COX-2 inhibitors, oral anticoagulants. False +ve reaction for urinary bile using diazo tab test. Not to be administered in renal impairment. Avoid use during 3rd trimester of pregnancy. Not recommended during pregnancy. Not to be used during lactation. Elderly or debilitated patients.

Blood & lymphatic & nervous system disorders; anaphylaxis; glucose intolerance in diabetics, hyponatremia, fluid retention; nervousness; eye irritation, reversible loss of color vision; ear pain; palpitation; hypotension, HTN; asthma, dyspnea; abdominal pain, diarrhea, nausea w/ or w/o vomiting; skin & subcutaneous tissue, renal & urinary disorders; edema; false +ve urobilinogen urine, abnormal liver function test; hypothermia in paed patients.

Interfered w/ anti-platelet effect of low dose aspirin. Enhanced oral anticoagulants response. Reduced efficacy of diuretics & other antihypertensive drugs eg, ACE inhibitors, AIIA & β-blockers. Increased risk of GI ulceration or bleeding w/ corticosteroids. Increased risk of nephrotoxicity w/ cyclosporine & tacrolimus. Changed effects of oral hypoglycemics. Elevated plasma lithium levels & reduced renal lithium clearance. Increased methotrexate plasma levels.

Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

M01AG01 - mefenamic acid ; Belongs to the class of non-steroidal antiinflammatory and antirheumatic products, fenamates.

C